Company Profile
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar.
Its portfolio also includes OLX104C for androgenic alopecia, OLX301A for age-related macular degeneration, OLX702A for metabolic dysfunction-associated steatohepatitis, OLX703A for hepatitis, and OLX301D for subretinal fibrosis.
The company has a license and collaboration agreement with Hansoh Pharmaceuticals. Its portfolio also includes development collaboration with Korea Institute of Technology, and research collaboration with the University of Virginia. Founded in 2010, The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals is headquartered in Suwon-si, South Korea.